Pulmonary cavitary disease due to Mycobacterium xenopi

•Pulmonary cavitary disease should not refer only to pulmonary tuberculosis.•M. xenopi is usually considered as a nonpathogenic contamination (especially, when isolated from bronchoalveolar lavage); our case highlights that M. xenopi should be considered as a cause of cavitary lesions, especially in...

Full description

Saved in:
Bibliographic Details
Published in:Infectious medicine 2022-03, Vol.1 (1), p.63-66
Main Authors: Abdallah, Yousri Ben, Belfeki, Nabil, Klopfenstein, Timothée, Zayet, Souheil
Format: Article
Language:English
Subjects:
COPD
Mycobacterium xenopi
Non-tuberculous mycobacteria
Pulmonary cavitary disease
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Pulmonary cavitary disease should not refer only to pulmonary tuberculosis.•M. xenopi is usually considered as a nonpathogenic contamination (especially, when isolated from bronchoalveolar lavage); our case highlights that M. xenopi should be considered as a cause of cavitary lesions, especially in patients with an underlying lung disease.•Drug susceptibility testing is not recommended in infections with M. xenopi and should not delay treatment.•Amikacin (aminoglycoside) should be associated with antimycobacterial treatment in case of M. Xenopi pulmonary disease with cavernous/cavitary disease. Non-tuberculous mycobacteria are a significant cause of pulmonary infections worldwide and can be clinically challenging. Mycobacterium xenopi (M. xenopi) has a low pathogenicity and usually requires immunosuppression or lung diseases. We describe herein a scarce case of pulmonary cavitary disease attributed to M. xenopi in a 57-year-old Caucasian patient with underlying structural lung disease successfully treated with rifampicin, ethambutol, clarithromycin, and amikacin.
ISSN:2772-431X
2772-431X
DOI:10.1016/j.imj.2021.11.001